Bolt Biotherapeutics Inc

NASDAQ:BOLT

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company is headquartered in Redwood City, California and currently employs 91 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. BDC-2034 is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). CEA is a well-known tumor antigen expressed in various solid tumors with significant unmet medical need. BDC-3042 is an agonist antibody targeting Dectin-2, which is an innate immune receptor found on the surface of macrophages. PD-L1 Boltbody ISAC focused on the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.